Systemic Lupus Erythematosus: Immunopathogenesis and Novel Therapeutic Targets. (July 2013)

• Record Type: Journal Article
• Authors: Beccastrini, E.; D'Elios, M.M.; Emmi, G.; Silvestri, E.; Squatrito, D.; Prisco, D.; Emmi, L.
• Is Part Of: International journal of immunopathology and pharmacology. Volume 26:Number 3(2013)
• Page Start: 585
• Page End: 596
• Publication Date: 2013-07
• Subjects: systemic lupus erythematosus -- SLE pathogenesis -- biologic therapies -- belimumab -- autoimmune diseases -- autoantibodies; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/039463201302600302
• Languages: English
• ISSNs: 0394-6320

Abstract

Systemic lupus erythematosus (SLE) is the prototype of autoimmune diseases with multiorgan involvement. SLE presents many genetic and epigenetic associations and the pathogenesis is characterized by a complex network of alterations affecting both adaptative and innate immunity. The disclosure of novel mechanisms of SLE pathogenesis suggested new therapeutic targets, based on interference with the cytokine pathways or on depletion of the immune cells.